title: [Treatment of stage Ta,T1 and Tis bladder tumors using Calmette-Guérin bacillus vaccine].
abstract: The authors report a series of 71 patients (sex ratio: 1F/4M, mean age: 68 years) with stage Ta (n = 20), T1a (n = 32), T1b (n = 14) and Tis (n = 5) bladder tumours treated by endoscopic resection followed by a course of intravesical BCG instillation (120 mg/week for 6 weeks). The mean follow-up was 15 months (3-36 months). The overall recurrence rate was 42%. A recurrence occurred in 50% of Ta (median time to recurrence: 10.1 months), 32% of T1a (median: 5.8 months), 65% of T1b (median: 7.3 months) and 20% of isolated Tis (median: 7 months). Disease progression was observed in 9% of stage T1 tumours. The following risk factors for recurrence were identified: stage T1b (p = 0.05), multifocal tumours (p = 0.05), resistance to previous chemotherapy (mitomycin C) (p = 0.001) and association with Tis for stages T1 (p < 0.02). The following risk factors for disease progression were identified: stage T1b (p < 0.001), grade III for stage T1 (p = 0.05) and association with Tis (p < 0.05). Ten patients (14%) developed transient BCGitis. BCG was found to be effective in the prophylaxis of recurrence of stage Ta, T1 and Tis bladder tumours. This treatment is proposed for recurrent stage Ta grade II and III tumours and stage T1 tumours in the presence of recognised risk factors. The high risk of progression for stage T1b grade III tumours associated with Tis demands rigorous surveillance.
authors.affiliation: Services d'Urologie (Hôpitaux Timone), Marseille.
authors.forename: D
authors.initials: D
authors.lastname: Bretheau
authors.forename: E
authors.initials: E
authors.lastname: Lechevallier
authors.forename: D
authors.initials: D
authors.lastname: Rossi
authors.forename: P
authors.initials: P
authors.lastname: Albert
authors.forename: M
authors.initials: M
authors.lastname: de Fromont
authors.forename: C
authors.initials: C
authors.lastname: Coulange
mesh_terms: D000283:Administration, Intravesical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001500:BCG Vaccine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004361:Drug Tolerance; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D009367:Neoplasm Staging; D011336:Probability; D012307:Risk Factors; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000517:prevention & control / Q000601:surgery / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents; D001500:BCG Vaccine